Regeneron Expects Acquired IPR&D Charge To Negatively Impact Each Of Q3 GAAP And Non-GAAP EPS By Approximately $0.78 - Filing
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals expects an acquired IPR&D charge to negatively impact its Q3 GAAP and non-GAAP EPS by approximately $0.78. This charge is related to a development milestone payment due upon the achievement of specified clinical proof-of-principle criteria for the Phase 1 ALN-APP program in early-onset Alzheimer’s disease, in collaboration with Alnylam Pharmaceuticals.
October 05, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron's Q3 earnings per share (both GAAP and non-GAAP) are expected to be negatively impacted by approximately $0.78 due to an acquired IPR&D charge. This could potentially affect the company's stock price.
The news directly mentions that Regeneron's Q3 earnings per share will be negatively impacted by an acquired IPR&D charge. This could potentially lead to a decrease in the company's stock price in the short term as lower earnings per share often lead to a decrease in a company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100